Targeting Helicases: Opportunities in Drug Development
Helicases, essential ATP-powered motor proteins that unwind DNA/RNA duplexes critical for replication, repair, transcription, and more—with ~95 human isoforms (31 DNA, 64 RNA)—are emerging as high-value drug targets in oncology and antivirals. Recent highlights include FDA Fast Track for ART6043 (Polθ inhibitor) in gBRCA-mutated breast cancer and promising Phase I/II data for WRN inhibitors like RO7589831 and HRO761, targeting MSI-H cancers (CRC, ovarian, endometrial, gastric), alongside eIF4A, DDX3, and DHX9; antivirals like Pritelivir and Amenamevir combat HSV/VZV resistance. Despite challenges from structural complexity, ATPase, active-site, and allosteric inhibitors are advancing rapidly in clinical pipelines
DNA and RNA helicases are essential motor proteins that use ATP to unwind nucleic acid duplexes—an indispensable step in nearly every aspect of nucleic acid metabolism: replication, repair, transcription, splicing, and more. With ~95 encoded in the human genome (31 DNA, 64 RNA), they're ripe for targeting in oncology and antivirals.
Recent Momentum Spotlight:
US FDA Fast Track for ART6043 (Polθ inhibitor) in gBRCA-mutated HER2-negative breast cancer (with Olaparib).
Positive Phase I/II data for WRN inhibitors: RO7589831 and HRO761.
Therapeutic Momentum:
Cancer: WRN (synthetically lethal in MSI-H tumors) leads with three inhibitors in trials—RO7589831, HRO761, NDI-219216—targeting CRC, ovarian, endometrial, gastric cancers. Positive safety/pharmacology for ART-6043 in Phase I/IIa. Others: eIF4A (DNA); DDX3, DHX9 (RNA).
Note: Novartis discontinued the development of their inhibitor HRO761, likely due to single-agent efficacy limits.
Antivirals: Pritelivir (AIC316) and Amenamevir (ASP2151) combat HSV/VZV, bypassing nucleoside resistance. Pipeline hits alphavirus nsP2, SARS-CoV-2, HCV.
🧪 Drug Discovery Strategies:
Helicases are challenging drug targets due to complex structure and large nucleic acid interfaces. Drug development approaches include:
·ATPase inhibitors: Potent but often nonspecific/toxic.
Active-site binders: Tough due to large protein-nucleic acid interfaces.
Allosteric inhibitors: More selective, gaining traction.
Despite structural hurdles, helicases are high-value targets—with clinical programs accelerating across oncology and viral diseases.
(Images - Freepik/ChatGPT)
Expert drug discovery and consulting services for biotech firms and Institutes
© 2025. All rights reserved.
Contact Us Tel: +91 98456 80674 Email: contact@bioprompt.in
Consulting Services
Training programs and workshop in Drug Discovery
Targets for Drug Discovery
Facilitation of Preclinical Studies
Location NB-3/44, Vijaya Enclave Bilekahalli, Bangalore - 560076 Karnataka, INDIA
All images are designed by freepik
